Clal Biotechnology reported ILS-5.3M in EBITDA for its fiscal quarter ending in December of 2022.





Ebitda Change Date
aTyr Pharma USD -26.58M 26.32M Sep/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
RedHill Biopharma USD 2.69M 108.46M Jun/2023